scholarly journals Treatment strategies in relapsed and refractory multiple myeloma: a focus on drug sequencing and ‘retreatment’ approaches in the era of novel agents

Leukemia ◽  
2011 ◽  
Vol 26 (1) ◽  
pp. 73-85 ◽  
Author(s):  
B Mohty ◽  
J El-Cheikh ◽  
I Yakoub-Agha ◽  
H Avet-Loiseau ◽  
P Moreau ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Treatment Strategies ◽  
Novel Agents ◽  
Refractory Multiple Myeloma

Treatment of Relapsed or Refractory Multiple Myeloma in the Era of Novel Agents

2012 ◽  
Vol 08 (02) ◽  
pp. 116 ◽  
Author(s):  
Federica Cavallo ◽  
Barbara Lupo ◽  
Antonio Palumbo ◽  
◽  
◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Early Phase ◽  
Second Generation ◽  
Treatment Strategies ◽  
New Drugs ◽  
Novel Agents ◽  
Refractory Multiple Myeloma ◽  
Appropriate Treatment ◽  
Prolonged Duration ◽  
Practical Guidelines

The introduction of highly effective novel agents has resulted in a significant improvement in the outcomes of patients with multiple myeloma. These agents, namely thalidomide, bortezomib and lenalidomide, have been extensively studied in the relapsed or refractory multiple myeloma (RRMM) setting and are now being increasingly incorporated into upfront treatment strategies. Second-generation novel agents such as carfilzomib and pomalidomide are being tested in early-phase studies, and preliminary results are encouraging. However, to date, there are no practical guidelines to help physicians choose the best approach for the treatment of RRMM, and direct comparisons between therapies at relapse are warranted. Moreover, despite the recent steps forward in the treatment of multiple myeloma, this disease remains incurable. This article provides an overview of the main studies incorporating novel agents as well as second-generation new drugs for the treatment of RRMM, and may guide physicians in the choice of the most appropriate treatment, associated with prolonged duration of remission and enhanced survival.

scholarly journals Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond

Leukemia ◽  
2017 ◽  
Vol 32 (2) ◽  
pp. 252-262 ◽  
Author(s):  
C S Chim ◽  
S K Kumar ◽  
R Z Orlowski ◽  
G Cook ◽  
P G Richardson ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Novel Agents ◽  
Refractory Multiple Myeloma

scholarly journals Carfilzomib Based Treatment Strategies in the Management of Relapsed/Refractory Multiple Myeloma with Extramedullary Disease

Cancers ◽  
2020 ◽  
Vol 12 (4) ◽  
pp. 1035 ◽  
Author(s):  
Xiang Zhou ◽  
Patricia Flüchter ◽  
Katharina Nickel ◽  
Katharina Meckel ◽  
Janin Messerschmidt ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Overall Response Rate ◽  
Treatment Strategies ◽  
Progression Free Survival ◽  
Serological Response ◽  
Free Survival ◽  
Refractory Multiple Myeloma ◽  
Extramedullary Disease ◽  
Heavily Pretreated ◽  
Pretreated Patients

Published experience with carfilzomib in patients with relapsed/refractory multiple myeloma (RRMM) and extramedullary disease (EMD) is still limited. The current study aimed to assess the efficacy and safety of carfilzomib containing therapy regimens in EMD. We retrospectively analyzed 45 patients with extramedullary RRMM treated with carfilzomib from June 2013 to September 2019. The median age at the start of carfilzomib was 64 (range 40–80) years. Twenty (44%) and 25 (56%) patients had paraosseous manifestation and EMD without adjacency to bone, respectively. The serological overall response rate (ORR) was 59%. Extramedullary response was evaluable in 33 patients, nine (27%) of them achieved partial remission (PR) (ORR = 27%). In 15 (33%) patients, we observed no extramedullary response despite serological response. The median progression-free survival (PFS) and overall survival (OS) were five (95% CI, 3.5–6.5) and ten (95% CI, 7.5–12.5) months, respectively. EMD without adjacency to bone was associated with a significantly inferior PFS (p = 0.004) and OS (p = 0.04) compared to paraosseous lesions. Carfilzomib based treatment strategies showed some efficacy in heavily pretreated patients with extramedullary RRMM but could not overcome the negative prognostic value of EMD. Due to the discrepancy between serological and extramedullary response, evaluation of extramedullary response using imaging is mandatory in these patients.

Novel Agents for Relapsed and/or Refractory Multiple Myeloma

2009 ◽  
Vol 15 (6) ◽  
pp. 485-493 ◽  
Author(s):  
Sheeba K. Thomas ◽  
Tiffany A. Richards ◽  
Donna M. Weber
Keyword(s):  
Multiple Myeloma ◽  
Novel Agents ◽  
Refractory Multiple Myeloma

scholarly journals Contemporary patient-tailored treatment strategies against high risk and relapsed or refractory multiple myeloma

EBioMedicine ◽  
2019 ◽  
Vol 39 ◽  
pp. 612-620 ◽  
Author(s):  
Fatih M. Uckun ◽  
Sanjive Qazi ◽  
Taner Demirer ◽  
Richard E. Champlin
Keyword(s):  
Multiple Myeloma ◽  
High Risk ◽  
Treatment Strategies ◽  
Refractory Multiple Myeloma ◽  
Tailored Treatment

scholarly journals The use of novel agents in the treatment of relapsed and refractory multiple myeloma

Leukemia ◽  
2009 ◽  
Vol 23 (12) ◽  
pp. 2222-2232 ◽  
Author(s):  
J P Laubach ◽  
A Mahindra ◽  
C S Mitsiades ◽  
R L Schlossman ◽  
N C Munshi ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Novel Agents ◽  
Refractory Multiple Myeloma

scholarly journals Treatment Strategies and Outcomes In Patients Treated For Relapsed Refractory Multiple Myeloma Over 3 Years: Premiere Study

2017 ◽  
Vol 20 (9) ◽  
pp. A417
Author(s):  
I Méndez ◽  
A Zagorska ◽  
E Artime ◽  
C Lefevre ◽  
B San José ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Treatment Strategies ◽  
Refractory Multiple Myeloma

scholarly journals Correction: Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond

Leukemia ◽  
2019 ◽  
Vol 33 (4) ◽  
pp. 1058-1059 ◽  
Author(s):  
C. S. Chim ◽  
S. K. Kumar ◽  
R. Z. Orlowski ◽  
G. Cook ◽  
P. G. Richardson ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Novel Agents ◽  
Refractory Multiple Myeloma
Sign in / Sign up

Export Citation Format

Share Document